Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma

NCT02203864 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: BIBW2 component A
BIOLOGICAL: BIBW2 component B

Sponsor

Boehringer Ingelheim